Accounting for Pharmacokinetic Variability of Certolizumab Pegol in Patients with Crohn’s Disease
- 28 March 2017
- journal article
- research article
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 56 (12) , 1513-1523
Abstract
Background Certolizumab pegol is an effective biologic for patients with Crohn’s disease (CD). Individual differences in certolizumab pegol apparent clearance (CL/F) affect exposure and possibly efficacy. A previously developed population pharmacokinetic (PK) model did not account for dynamic changes in clinical parameters during therapy. Objective The aim of this study was to refine the existing PK model to capture the time-varying influence of covariates. Methods Data collected from 2157 Crohn’s disease patients in nine studies were analyzed using nonlinear mixed-effects modeling software (NONMEM). Certolizumab pegol concentration–time data were described by a one-compartment PK model with first-order absorption, and one-compartment disposition with linear, time-dependent elimination using antidrug antibody (ADAb) concentration as a continuous variable. Results The final dataset consisted of 12,926 analyzable records. Parameter estimates were absorption rate constant 1.83/day, CL/F 0.527 L/day, and apparent volume of distribution (V/F) 8.33 L. ADAb concentration (2.5–214 units/mL) increased the median CL/F by 142–174%. For a typical patient, body weight (46.8–100.5 kg) increased the median CL/F and V/F from 82 to 120%. Albumin (32–48 g/L) decreased and C-reactive protein (0.5–54.0 mg/L) increased the median CL/F from 123 to 85% and from 83 to 113%, respectively. Between-patient variability of CL/F was 19.6%. Conclusions By incorporating time-varying covariates, this population PK model reduces between-patient variability on CL/F estimates, and the relative influence of ADAb can now be assessed. As Crohn’s disease patient covariates are often time-dependent, this model is more reflective of patient drug exposure with sustained treatment.Keywords
Funding Information
- UCB Pharma
This publication has 31 references indexed in Scilit:
- Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2012
- Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn’s diseaseAlimentary Pharmacology & Therapeutics, 2011
- Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized TrialClinical Gastroenterology and Hepatology, 2011
- Pharmacokinetic Properties of Infliximab in Children and Adults with Crohn's Disease: A Retrospective Analysis of Data from 2 Phase III Clinical TrialsClinical Therapeutics, 2011
- Review article: causative factors and the clinical management of patients with Crohn’s disease who lose response to anti-TNF-α therapyAlimentary Pharmacology & Therapeutics, 2011
- Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trialsAlimentary Pharmacology & Therapeutics, 2009
- Tumor necrosis factor antagonist mechanisms of action: A comprehensive reviewPharmacology & Therapeutics, 2008
- A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s DiseaseGastroenterology, 2005
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation.Journal of Clinical Investigation, 1987